Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Sadif Analytics Prime
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celldex Therapeutics Inc Announces Publication Of Preliminary Data From Phase 2 ReACT Study


Monday, 11 Nov 2013 07:01am EST 

Celldex Therapeutics Inc announced the preliminary data from ReACT: a Phase 2 Study of Rindopepimut Vaccine (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma, was published in the 2013 abstract supplement to the journal Neuro-Oncology. ReACT is a Phase 2 study designed to determine if adding rindopepimut to standard of care Avastin (bevacizumab) improves the outcomes for patients with recurrent EGFRvIII-positive glioblastoma. In August, 2013, Celldex announced that enrollment had been completed in an initial cohort (n=25) of Avastin refractory patients and that, based on early evidence of anti-tumor activity, the Company decided to add an expansion cohort of approximately 75 patients (Group 2C) to better characterize the potential activity of rindopepimut in this refractory patient population. Study endpoints include six month progression free survival rate, objective response rate, overall survival and safety and tolerability. 

Company Quote

15.5
0.09 +0.58%
24 Oct 2014